Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The investigators reported previously that epigenetic activation of organic cation
transporter (OCT2) by decitabine sensitizes RCC cells to oxaliplatin both in vitro and in
xenografts. The objective of this phase II clinical trial is to investigate the efficacy and
safety of sequential combination therapy with decitabine and oxaliplatin in patients with
relapsed/metastatic renal cell carcinoma who progressed on standard of care.